ERBB3 and lung cancer: A previous study indicated that treatment of Capmatinib over a period (e.g., 24 h) led to a dose-dependent increase of HER3 protein even though Capamtinib had the ability to suppress phosphorylation of EGFR and HER3 effectively in MET amplified H1993 lung cancer cells [26].